UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

Frontiers in medicine, 2021-04, Vol.8, p.615978-615978

2021

Volltextzugriff (PDF)

Eligibility of persons who inject drugs for treatment of hepatitis C virus infection

World journal of gastroenterology : WJG, 2014-09, Vol.20 (36), p.12722-12733

2014

Volltextzugriff (PDF)

Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement

Journal of hepatology, 2012-12, Vol.57 (6), p.1379-1390

2012

Volltextzugriff (PDF)

Hepatitis C prevalence in incarcerated settings between 2013–2021: a systematic review and meta-analysis

BMC public health, 2022-11, Vol.22 (1), p.1-2159, Article 2159

2022

Volltextzugriff (PDF)

Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium

PloS one, 2020-07, Vol.15 (7), p.e0234740-e0234740

2020

Volltextzugriff (PDF)

Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach

BMC infectious diseases, 2022-04, Vol.22 (1), p.397-397, Article 397

2022

Volltextzugriff (PDF)

Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries

Harm reduction journal, 2018-05, Vol.15 (1), p.25-25, Article 25

2018

Volltextzugriff (PDF)

A multicentre interventional study to assess blood-borne viral infections in Belgian prisons

BMC infectious diseases, 2021-07, Vol.21 (1), p.708-708, Article 708

2021

Volltextzugriff (PDF)

On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era

BMC public health, 2021-08, Vol.21 (1), p.1-1574, Article 1574

2021

Volltextzugriff (PDF)

The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination

International journal of infectious diseases, 2021-04, Vol.105, p.217-223

2021

Volltextzugriff (PDF)

Eliminating viral hepatitis C in Belgium: the micro-elimination approach

BMC infectious diseases, 2020-02, Vol.20 (1), p.181-12, Article 181

2020

Volltextzugriff (PDF)

Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length Genomes

Viruses, 2023-12, Vol.15 (12), p.2391

2023

Volltextzugriff (PDF)

Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium

Harm reduction journal, 2021-05, Vol.18 (1), p.54-54, Article 54

2021

Volltextzugriff (PDF)

Hepatitis C reinfection in former and active injecting drug users in Belgium

Harm reduction journal, 2021-10, Vol.18 (1), p.1-102, Article 102

2021

Volltextzugriff (PDF)

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

Journal of hepatology, 2014-02, Vol.60 (2), p.392-420

2014

Volltextzugriff (PDF)

Resource use and cost of hepatitis C-related care

European journal of gastroenterology & hepatology, 2012-10, Vol.24 (10), p.1191-1198

2012

Volltextzugriff (PDF)

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

BMC infectious diseases, 2017-06, Vol.17 (1), p.420-12, Article 420

2017

Volltextzugriff (PDF)

FRI-526 - The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients

Journal of hepatology, 2023-06, Vol.78, p.S828-S829

2023

Volltextzugriff (PDF)

The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients

Journal of hepatology, 2023-06, Vol.78, p.S828-S829

2023

Volltextzugriff (PDF)

SAT-196 A significant decrease in steatosis using non-invasive measurements during monitoring for life style changes in patients with MASLD: interim 6 m results of a monocentric study

Journal of hepatology, 2024-06, Vol.80, p.S604-S604

2024

Volltextzugriff (PDF)

The fibrosis-4 cut-off value for significant fibrosis is dependent on the type of non-alcoholic fatty liver disease patients

Journal of hepatology, 2022-07, Vol.77, p.S459-S460

2022

Volltextzugriff (PDF)

Global genotype distribution of hepatitis C viral infection among people who inject drugs

Journal of hepatology, 2016-12, Vol.65 (6), p.1094-1103

2016

Volltextzugriff (PDF)

An adult patient with alcoholic liver cirrhosis and IgA vasculitis

Acta gastro-enterologica belgica, 2018-04, Vol.81 (2), p.342-343

2018

Volltextzugriff (PDF)

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

The New England journal of medicine, 2021-10, Vol.385 (17), p.1547-1558

2021

Volltextzugriff (PDF)

FRI026 - The prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus

Journal of hepatology, 2020-08, Vol.73, p.S412-S413

2020

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(95)

Publikationsform

Artikel
(101)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

Eligibility of persons who inject drugs for treatment of hepatitis C virus infection

Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement

Hepatitis C prevalence in incarcerated settings between 2013–2021: a systematic review and meta-analysis

Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium

Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach

Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries

A multicentre interventional study to assess blood-borne viral infections in Belgian prisons

On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era

The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination

Eliminating viral hepatitis C in Belgium: the micro-elimination approach

Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length Genomes

Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium

Hepatitis C reinfection in former and active injecting drug users in Belgium

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

Resource use and cost of hepatitis C-related care

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

FRI-526 - The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients

The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients

SAT-196 A significant decrease in steatosis using non-invasive measurements during monitoring for life style changes in patients with MASLD: interim 6 m results of a monocentric study

The fibrosis-4 cut-off value for significant fibrosis is dependent on the type of non-alcoholic fatty liver disease patients

Global genotype distribution of hepatitis C viral infection among people who inject drugs

An adult patient with alcoholic liver cirrhosis and IgA vasculitis

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

FRI026 - The prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus

Suchergebnisse filtern